| Literature DB >> 31367347 |
Nobuyuki Tetsuka1,2, Aki Hirabayashi3, Akane Matsumoto1, Keisuke Oka1,2, Yuki Hara2,4, Hiroshi Morioka1, Mitsutaka Iguchi1, Yuka Tomita1, Masato Suzuki3, Keigo Shibayama5, Tetsuya Yagi1,2.
Abstract
Background: To clarify the molecular epidemiology of carbapenem-resistant Enterobacter cloacae complex (CREC) and the risk factors for acquisition of carbapenemase-producing E. cloacae complex (CPEC).Entities:
Keywords: Carbapenem-resistant Enterobacteriaceae; Carbapenemase; Carbapenemase-producing Enterobacteriaceae; Enterobacter cloacae complex; Molecular epidemiology; Multilocus sequence typing; Plasmid; Repetitive extragenic palindromic polymerase chain reaction; Whole-genome sequencing; β-Lactamase
Mesh:
Substances:
Year: 2019 PMID: 31367347 PMCID: PMC6657070 DOI: 10.1186/s13756-019-0578-3
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Fig. 1Annual incidence of carbapenem-resistant Enterobacter cloacae complex cases from April 2012 to March 2016 in Nagoya University Hospital. Abbreviations: CPEC, carbapenemase-producing Enterobacter cloacae complex
Baseline characteristics and health care exposure of carbapenem-resistant Enterobacter cloacae complex cases
| CREC ( | OR (95% CI) | |||||
|---|---|---|---|---|---|---|
| CPEC ( | Non-CPEC ( | |||||
| Baseline characteristics | ||||||
| Female sex | 8 | 7 | 1.14 (0.26–5.05) | 1 | ||
| Age (years), median (range) | 65 | (0–82) | 71 | (0–89) | 0.112 | |
| Age group (years) | 0.431 | |||||
| 0–18 | 3 | 1 | ||||
| 19–49 | 3 | 1 | ||||
| 50–64 | 4 | 2 | ||||
| 65–79 | 8 | 13 | ||||
| ≧80 | 1 | 2 | ||||
| Days from admission to positive culture (days), median (range) | 26.5 | (1–352) | 12 | (0–52) | 0.008 | |
| Underlying conditions | 20 | 17 | 0.231 | |||
| History of surgery | 17 | 12 | 3.20 (0.58–23.2) | 0.155 | ||
| Any malignancy | 6 | 9 | 0.49 (0.10–2.12) | 0.333 | ||
| Chronic renal insufficiency | 4 | 4 | 0.93 (0.15–6.04) | 0.939 | ||
| Neurological disorder | 5 | 3 | 1.75 (0.28–13.3) | 0.695 | ||
| Congestive heart failure | 3 | 4 | 0.67 (0.08–4.67) | 0.695 | ||
| Diabetes | 3 | 3 | 0.94 (0.11–8.11) | 1 | ||
| Transplant recipient | 3 | 1 | 3.09 (0.22–176) | 0.605 | ||
| Cirrhosis | 1 | 1 | 0.95 (0.01–78.4) | 1 | ||
| Decubitus or pressure ulcer | 0 | 1 | 0.487 | |||
| Chronic lung disease | 1 | 0 | 1 | |||
| Liver failure | 1 | 0 | 1 | |||
| Urinary tract problems or abnormalities | 0 | 1 | 0.487 | |||
| Myocardial infarction | 1 | 0 | 1 | |||
| HIV positive | 0 | 1 | 0.487 | |||
| Health care exposure | ||||||
| Administration of antibiotics within 30 days | 18 | 16 | 1.67 (0.17–22.3) | 0.661 | ||
| Acute care hospitalization within 3 months | 10 | 13 | 0.47 (0.10–2.03) | 0.333 | ||
| Indwelling devices (2 calendar days prior to culture) | 18 | 12 | 5.03 (0.78–57.7) | 0.065 | ||
| Central venous catheter | 12 | 7 | 2.50 (0.60–11.4) | 0.205 | ||
| Nasogastric tube | 11 | 7 | 2.06 (0.49–9.17) | 0.341 | ||
| Drainage tube | 9 | 8 | 1.12 (0.27–4.80) | 1 | ||
| Intraperitoneal drainage tube | 6 | 6 | 0.93 (0.19–4.50) | 1 | ||
| Chest drainage tube | 4 | 1 | 4.34 (0.38–233) | 0.342 | ||
| Percutaneous transhepatic biliary drainage tube | 3 | 1 | 3.09 (0.22–176) | 0.605 | ||
| Endoscopic nasobiliary drainage tube | 1 | 2 | 0.46 (0.007–9.51) | 0.605 | ||
| Urinary catheter | 12 | 4 | 5.36 (1.14–30.9) | 0.023 | ||
| Intubation (include tracheostomy) | 12 | 3 | 7.53 (1.47–53.8) | 0.008 | ||
| Haemodialysis | 2 | 4 | 0.43 (0.03–3.46) | 0.407 | ||
Note. OR Odds ratio, CI Confidence interval, CREC Carbapenem-resistant Enterobacter cloacae complex, CPEC Carbapenemase-producing Enterobacter cloacae complex
Culture source, clinical diagnosis, and outcome among carbapenem-resistant Enterobacter cloacae complex cases
| CREC ( | OR (95% CI) | |||
|---|---|---|---|---|
| CPEC ( | Non-CPEC ( | |||
| Culture source | ||||
| Sterile site | 2 | 3 | ||
| Blood | 1 | 2 | 0.46 (0.007–9.51) | 0.605 |
| Abscess | 1 | 0 | 1 | |
| Vascular graft | 0 | 1 | 0.487 | |
| Non-sterile site | 18 | 16 | ||
| Sputum | 11 | 4 | 4.40 (0.94–25.0) | 0.048 |
| Peritoneal fluid (not punctured) | 2 | 4 | 0.43 (0.03–3.46) | 0.407 |
| Urine | 1 | 3 | 0.29 (0.05–4.02) | 0.342 |
| Bile | 1 | 2 | 0.46 (0.007–9.51) | 0.605 |
| Oral swab | 0 | 1 | 0.487 | |
| Stool | 2 | 3 | 0.60 (0.04–5.96) | 0.661 |
| Clinical diagnosis | ||||
| Colonisation | 11 | 7 | 2.06 (0.49–9.17) | 0.341 |
| Infection | 9 | 12 | ||
| Pneumonia | 5 | 2 | 2.76 (0.38–33.1) | 0.407 |
| Peritonitis | 1 | 5a | 0.15 (0.003–1.60) | 0.092 |
| Pyelonephritis | 0 | 3 | 0.106 | |
| Bacteremia | 1 | 2a | 0.46 (0.007–9.51) | 0.605 |
| Cholangitis | 1 | 0 | 1 | |
| Vascular graft infection | 0 | 1 | 0.487 | |
| Abscess | 1 | 0 | 1 | |
| Outcome | ||||
| Required intensive care unit stay in the 7 days after positive culture | 10 | 7 | 1.67 (0.40–7.48) | 0.523 |
| Died at the end of the 30-day evaluation | 1 | 2 | 0.46 (0.007–9.51) | 0.605 |
| Among sterile site positive culture | 0 | 1 | ||
| Among non-sterile site positive culture | 1 | 1 | ||
| Died during hospitalisation | 3 | 2 | 1.48 (0.15–19.9) | 1 |
| Among sterile site positive culture | 1 | 1 | ||
| Among non-sterile site positive culture | 2 | 1 | ||
aOne case had peritonitis with bacteremia
Note. OR Odds ratio, CI Confidence interval, CREC Carbapenem-resistant Enterobacter cloacae complex, CPEC Carbapenemase-producing Enterobacter cloacae complex
Fig. 2Phylogenetic tree based on repetitive extragenic palindromic (REP)-PCR of carbapenem-resistant Enterobacter cloacae complex with hsp60-based genetic cluster, subspecies, sequence type (ST) classified by multilocus sequence typing and identification of the carbapenemase gene. Genetic relatedness was determined by a similarity cut-off > 95%. aSpecies and subspecies were determined with reference to the report by Chavda et al. bNewly registered in this study
Replicon type, integron type, antimicrobial resistance genes, heavy metal resistance genes and toxin/antitoxin system on the analysed plasmids
| Plasmid | Host | Plasmid replicon | Integron type | Antimicrobial resistance genes | Heavy metal resistance genes | Toxin/antitoxin system | ||
|---|---|---|---|---|---|---|---|---|
| Mercury | Arsenic | Tellurite | ||||||
| pNUH12_ECL006_1 | 6 | IncHI2A | Class 1 | HipBA | ||||
| pNUH15_ECL011_1 | 11 | IncHI2A | Class 1 | |||||
| pNUH15_ECL020_1 | 20 | IncHI2A | Class 1 | HipBA | ||||
| pNUH14_ECL028_1 | 28 | IncHI2A | Class 1 | HipBA | ||||
| pNUH13_ECL030_1 | 30 | IncHI2A | Class 1 | HipBA | ||||
| pNUH15_ECL032_1 | 32 | IncHI2A | Class 1 | HipBA | ||||
| pNUH15_ECL035_1 | 35 | IncHI2A | Class 1 | HipBA | ||||
Fig. 3Linear comparison of blaIMP-1-carrying plasmid sequences from Enterobacter cloacae complex strains was performed with BLAST and visualized with Easyfig (http://mjsull.github.io/Easyfig/). Red, yellow, green, and blue arrows indicate the blaIMP-1 gene, other antimicrobial resistant genes (ARG), type IV secretion system (T4SS)-associated genes for conjugation, and mobile gene elements (MGE) detected from CDS annotations, respectively. Structural features of a class 1 integron containing blaIMP-1 are shown, and the structures are almost identical in six plasmids, except for pNUH14_ECL028_1